Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Saroglitazar magnesium 4mg
DRUG
2 trials
Sponsors
Zydus Therapeutics Inc.
Conditions
Healthy
Non Alcoholic Steatohepatitis
Phase 1
A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers
Completed
NCT04045769
Zydus Therapeutics Inc.
Healthy
Start: 2019-08-19
End: 2019-12-02
Updated: 2020-04-21
Phase 2
Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
Completed
NCT03863574
Zydus Therapeutics Inc.
Non Alcoholic Steatohepatitis
Start: 2019-06-12
End: 2020-03-20
Updated: 2024-10-15
Related Papers
Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
2023-01-31
26 citations
From cause to consequence: Insights into incident diabetes mellitus after hepatic steatosis
Clinical Liver Disease
2023-01-13
2 citations